跳至主要内容
临床试验/NCT05051475
NCT05051475已完成不适用

Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus - the Patients' Perspective: a Randomized Controlled Trial Assessing Procedural Acceptability and Safety (RATE Study)

Centre of Postgraduate Medical Education2 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
62
试验地点
2
主要终点
Level of late post-procedural pain (at day 30 after treatment)

研究概览

简要总结

This study compares patients' acceptability and safety of two established endoscopic methods for treating dysplastic Barrett's esophagus: radiofrequency ablation versus hybrid argon plasma coagulation.

详细描述

Both endoscopic radiofrequency ablation (RFA) and argon plasma coagulation (APC) are established treatment modalities for dysplastic Barrett's esophagus. Recently, a modification of the APC method has emerged, which involves a submucosal injection of saline preceding the thermal ablation (hybrid-APC; h-APC). This allows to increase the procedure's safety and presumably reduces the patients' post-procedural discomfort. Although both RFA and h-APC are characterized by high effectiveness in eradicating Barrett's segments, limited data compares the patient-related aspects of the procedures. To fill this knowledge gap, we set out a single-center randomized-controlled trial to compare procedural acceptability, safety, and impact on the quality of life, of the two methods.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female subjects over 18 years
  • Histologically and endoscopically proven Barrett's esophagus requiring ablation therapy according to the current guidelines
  • General health status sufficient to perform an endoscopic procedure (ASA I-III)

排除标准

  • Primary or secondary coagulopathy, with INR>1.5 and/or platelet count of <75,
  • Anticoagulation therapy (e.g. warfarin) for high-risk condition and unable to withhold the medication temporarily
  • Recent myocardial infraction or other significant cardiovascular event within 6 months prior to recruitment
  • Patients under long-term care and/or within nursing facilities (e.g. psychosocial disorders, mental retardation)
  • Any history of esophageal resection surgery
  • Esophageal varices

结局指标

主要结局

Level of late post-procedural pain (at day 30 after treatment)

时间窗: Measured at day 30 after the procedure

Post-procedural chest pain evaluated by the numeric analog scale (NAS) from score 0 (no pain) to 10 (worst possible pain)

Level of post-procedural pain at day 7 after treatment

时间窗: Measured at day 7 after the procedure

Post-procedural chest pain evaluated by the numeric analog scale (NAS) from score 0 (no pain) to 10 (worst possible pain)

Level of post-procedural pain

时间窗: Measured at any time point before given anesthesia for the procedure and immidietly after the procedure.

Change in chest pain evaluated by the numeric analog scale (NAS) from score 0 (no pain) to 10 (worst possible pain) before the procedure and immidietly after (30-60 minutes) the procedure.

次要结局

  • Level of post-procedural dysphagia(Measured before the procedure, immidietly after (30-60mins), and at day 7, and day 30 after the procedure.)
  • Level of post-procedural quality of life(Measured before the procedure, immidietly after (30-60mins), and at day 7, and day 30 after the procedure.)
  • The rate of complications(Measured during the prcoedure, immidietly after the procedure and at day 7 and day 30 after the procedure during follow-up)

研究者

发起方
Centre of Postgraduate Medical Education
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验